<DOC>
	<DOCNO>NCT02180763</DOCNO>
	<brief_summary>The purpose study compare satisfaction ( LQI questionnaire , factor I : treatment interference ) PID patient receive subcutaneous injection Gammanorm® 165 mg/mL accord delivery device .</brief_summary>
	<brief_title>Gammanorm Quality Life Study Immunodeficient Patients Using Rapid Push Pumps</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Adult patient ( ≥ 18 year ) Presenting primary immunodeficiency Having receive subcutaneous injection immunoglobulin home use automatic pump least 1 month time inclusion For investigator decides maintain immunoglobulin replacement therapy subcutaneous injection Gammanorm® 165 mg/mL home Having sign informed consent form Patient currently participate another interventional study time inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Primary Immunodeficiency , PID</keyword>
</DOC>